BANC

Banc of California

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Financial Services

industry

Banks - Regional

Exchange

NYSE

County of HQ

China

Next Earnings Date

04/22/26

Business Summary

Akso Health operates in medical distribution within the Healthcare sector, acting as an intermediary between manufacturers and healthcare providers. The model typically relies on sourcing medical devices or health-related products and distributing them through regional channels, generating revenue through markup spreads and volume throughput. In theory, scale drives purchasing leverage and logistics efficiency, allowing margin expansion as distribution density improves. The moat, if it develops, would come from supplier relationships, regulatory approvals, and embedded distribution networks — but sustained profitability is required before that moat becomes credible.

VALUATION

P/E

15.8

Market Cap ($M USD)

$2,844

Forward P/E

8.9

PEG

0.3

PRICE TO SALES

2.7

PRICE TO BOOK

0.9

EV / EBITDA

-

5-Year Average P/E

DIVIDEND

Yield

2.30%

Annual Payout

$0.48

Payout Ratio

33.90%

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

14.90%

Financial Health & Profitability

Earnings Per Share

$1.18

Next Year EPS Growth Estimate

$2.07

Next Year Revenue Growth Estimate

7.90%

Return on Equity (ROE)

5.30%

Operating Margin

34.80%

Debt-to-Equity

0.9

Piotroski F-Score

6

Altman Z-Score

0.1

Return on Invested Capital (ROIC)

13.60%%

Current Ratio

-

Quick Ratio

Gainseekers Quantitative Analysis

Summary

This is not a GARP story — it’s a distressed, speculative micro-cap disguised by a massive balance sheet anomaly. With no P/E, no Forward P/E, negative EPS of -1,333.50, and an operating margin of -68.40%, the company is deeply unprofitable and burning capital. A Price/Sales ratio of 71.4 and Price/Book of 9.9 are extreme relative to a business with negative ROIC of -68.40%, suggesting the market is pricing in a dramatic turnaround that has not materialized. The only statistical outlier is the Altman Z-Score of 84.4, implying extraordinarily low bankruptcy risk, but that safety signal clashes with the income statement collapse — this is a balance-sheet-heavy company with no earnings power, and until profitability exists, valuation support is speculative at best.

AI Exposure / Tech Reliance

As a Medical Distribution company within Healthcare, AI integration would primarily impact logistics optimization, inventory forecasting, and procurement automation. However, with an operating margin of -68.40%, the company currently lacks evidence of operational efficiency that would suggest successful technology leverage. Without positive returns, modernization remains theoretical rather than demonstrated.

The Bull Case

A deep value investor could argue that the Piotroski F-Score of 6 signals middling but not distressed financial quality, while the Altman Z-Score of 84.4 suggests an extremely strong solvency position. The negative Debt/Equity ratio of -32.50% implies an unconventional capital structure that may reflect balance sheet strength rather than leverage stress. A current ratio of 1.5 indicates adequate short-term liquidity, meaning near-term obligations are covered. If operational losses normalize and sales scale into the existing asset base, even modest margin recovery from -68.40% could create explosive operating leverage given the $1,961M market cap pricing in long-duration optionality.

The Bear Case

The bear case is overwhelming. EPS of -1,333.50, operating margin of -68.40%, and ROIC of -68.40% signal systemic value destruction, not cyclical weakness. A Price/Sales of 71.4 for a company with negative growth visibility and no forward earnings metrics is extreme and difficult to justify under any disciplined valuation framework. There is no Forward P/E, no PEG, no analyst target, no institutional ownership data, and no short interest transparency — this informational vacuum combined with persistent losses makes the equity highly speculative and structurally risky.

Market Sentiment & Smart Money

Short Interest %

6.40%

Analyst Consensus

1.42

Average Analyst Price Target

$22.64

Institutional Ownership %

98.40%

1-Year Beta

1.27

Insider Buying % (6 Mo)

0.90%%

Distance to 52-Week High

85.30%%

Distance to 52-Week Low

155.70%%